Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature

Psoriasis is a relatively common immune-mediated chronic inflammatory skin disease. It is well known that interferon-beta, a drug used in the management of relapsing-remitting multiple sclerosis, could exacerbate or induce de novo psoriasis. There is limited evidence in the literature based only on...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambrianides, Sakis, Kinnis, Evgenios, Leonidou, Eleni, Pantzaris, Marios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180259/
https://www.ncbi.nlm.nih.gov/pubmed/30323758
http://dx.doi.org/10.1159/000492891
Descripción
Sumario:Psoriasis is a relatively common immune-mediated chronic inflammatory skin disease. It is well known that interferon-beta, a drug used in the management of relapsing-remitting multiple sclerosis, could exacerbate or induce de novo psoriasis. There is limited evidence in the literature based only on case reports that natalizumab could induce or aggravate psoriasis. In this case study, we present a 33-year-old patient who developed plaque psoriasis during natalizumab treatment.

Ejemplares similares